ASCENDIS PHARMA A/S — Credit Rating and Financial Key Figures
CVR number: 29918791
Tuborg Boulevard 12, 2900 Hellerup
tel: 36944486
Income statement (mEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 6.95 | 7.78 | 51.17 | 266.72 | 363.64 |
| Costs of manufacturing | -3.52 | -12.14 | -44.40 | -44.26 | |
| Gross profit | 6.95 | 4.25 | 39.04 | 222.32 | 319.38 |
| Costs of marketing | - 160.18 | - 221.23 | - 264.41 | - 291.14 | |
| Other operating expenses | - 337.57 | - 295.87 | - 379.62 | - 413.45 | - 307.00 |
| EBIT | - 330.62 | - 451.79 | - 561.81 | - 455.54 | - 278.76 |
| Other financial income | 1.81 | 59.72 | 52.18 | 43.86 | 25.61 |
| Other financial expenses | -80.84 | -3.91 | -50.49 | -44.06 | - 100.03 |
| Net income from associates (fin.) | -9.52 | 12.04 | -17.70 | -18.39 | -20.06 |
| Pre-tax profit | - 419.17 | - 383.94 | - 577.82 | - 474.14 | - 373.24 |
| Income taxes | 0.22 | 0.37 | -5.38 | -7.30 | -4.84 |
| Net earnings | - 418.95 | - 383.58 | - 583.19 | - 481.45 | - 378.08 |
Assets (mEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible rights | 5.72 | 5.27 | 4.83 | 4.42 | 4.03 |
| Intangible assets total | 5.72 | 5.27 | 4.83 | 4.42 | 4.03 |
| Other tangible assets | 108.11 | 126.05 | 129.09 | 110.63 | 98.71 |
| Tangible assets total | 108.11 | 126.05 | 129.09 | 110.63 | 98.71 |
| Participating interests | 9.18 | 38.34 | 22.93 | 5.69 | 13.57 |
| Other non-current investments | 115.28 | 107.56 | 7.49 | ||
| Investments total | 124.46 | 145.91 | 30.42 | 5.69 | 13.57 |
| Non-current other receivables | 1.38 | 1.81 | 1.92 | 2.13 | 2.32 |
| Long term receivables total | 1.38 | 1.81 | 1.92 | 2.13 | 2.32 |
| Inventories total | 75.41 | 130.67 | 208.93 | 295.61 | |
| Current trade debtors | 0.39 | 2.20 | 11.91 | 35.87 | 166.28 |
| Prepayments and accrued income | 13.99 | 25.23 | 31.72 | 38.58 | 28.27 |
| Current other receivables | - 108.32 | 255.89 | 303.52 | 26.37 | 9.38 |
| Current deferred tax assets | 0.89 | 0.88 | 0.80 | 1.77 | |
| Short term receivables total | -93.94 | 284.21 | 348.03 | 101.63 | 205.71 |
| Current other shares and ownership | 249.56 | ||||
| Cash and bank deposits | 584.52 | 446.27 | 444.77 | 392.16 | 559.54 |
| Cash and cash equivalents | 834.08 | 446.27 | 444.77 | 392.16 | 559.54 |
| Balance sheet total (assets) | 979.79 | 1 084.92 | 1 089.74 | 825.59 | 1 179.49 |
Equity and liabilities (mEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 7.22 | 7.65 | 7.67 | 7.75 | 8.15 |
| Other reserves | 831.49 | 875.99 | 255.67 | - 153.45 | - 113.86 |
| Retained earnings | 418.95 | 383.58 | 583.19 | 481.45 | 378.08 |
| Profit of the financial year | - 418.95 | - 383.58 | - 583.19 | - 481.45 | - 378.08 |
| Shareholders equity total | 838.71 | 883.63 | 263.35 | - 145.70 | - 105.71 |
| Non-current loans from credit institutions | 97.97 | 95.40 | 223.00 | 365.08 | |
| Non-current leasing loans | 85.12 | 95.40 | |||
| Non-current other liabilities | 3.16 | 2.96 | -81.19 | 5.95 | 5.00 |
| Non-current deferred tax liabilities | 5.83 | 7.26 | |||
| Non-current liabilities total | 88.28 | 100.93 | 109.61 | 234.78 | 377.34 |
| Current loans from credit institutions | 7.00 | 13.79 | 14.17 | 33.33 | |
| Current leasing loans | 6.86 | 13.79 | |||
| Short-term deferred tax liabilities | 0.30 | 0.20 | 5.49 | 2.30 | 1.22 |
| Other non-interest bearing current liabilities | 45.28 | 89.37 | 676.37 | 686.13 | 773.23 |
| Current provisions | 1.19 | 7.34 | 32.72 | 99.15 | |
| Accruals and deferred income | 0.36 | 2.60 | 1.18 | 0.94 | |
| Current liabilities total | 52.80 | 100.36 | 716.78 | 736.51 | 907.86 |
| Balance sheet total (liabilities) | 979.79 | 1 084.92 | 1 089.74 | 825.59 | 1 179.49 |
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.